AURKA copy number showed a modest level of gain in approximately 50% of NSCLC, with a frequency unaffected by EGFR, KRAS, or TP53 mutational status (Fig. 1D; Supplementary Table S2). This evidence concerns the gene KRAS and non-small cell lung carcinoma.